The 2nd CKBF (China-Korea Bio Investment & Licensing Forum) was successfully hold in Hangzhou on Nov.6th 2026, and the CKBF was initiated by DreamCIS, Angine, Tigermed and KRDR in an annual base.
There are 12 Korean companies gave the pitch during the 2nd CKBF with more than 40 Chinese Pharma BD and Investor invited by Angine to explore the potential BD partnership.
Angine strong believes there will be a lot of synergy between Korean Bioventure and Chinese Pharma. Angine will give more devotion to build up the partner ecosystem between two countries with facilitating the BD transactions and investment after the event.
Looking forward to CKBF 2027.
